Thursday, April 4 | 11am EDT | 1 hour | Hosted by: Clinical Leader
In November 2022, FDA Oncology Center of Excellence (OCE) introduced Project FrontRunner to emphasize the need for new cancer drugs to be accessible to patients with early advanced metastatic cancer in an earlier clinical setting. The aim is to provide an alternative development pathway for faster approval of new treatments that does not follow the existing paradigm in which most treatments are developed for patients who have already received multiple prior lines of therapy or have failed available treatment options. Eligible development programs should have the potential to provide clinically meaningful treatment effects and/or have better safety profiles than the current “standards of care.”
